Cost‐Effectiveness of Nivolumab in Recurrent Metastatic Head and Neck Squamous Cell Carcinoma

BACKGROUND. Treatment options for patients with platinum‐refractory, recurrent, metastatic head and neck squamous cell carcinoma (r/m HNSCC) are limited and prognosis is poor. The recent CheckMate 141 clinical trial demonstrated that nivolumab, an anti‐programmed cell death protein 1 monoclonal anti...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Pubblicato in:Oncologist
Autori principali: Zargar, Mahdi, McFarlane, Thomas, Chan, Kelvin K.W., Wong, William W.L.
Natura: Artigo
Lingua:Inglês
Pubblicazione: AlphaMed Press 2017
Soggetti:
Health Outcomes and Economics of Cancer Care
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC5813741/
https://ncbi.nlm.nih.gov/pubmed/29021380
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1634/theoncologist.2017-0277
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi